Lung Cancer Incidence in Never Smokers
Top Cited Papers
- 10 February 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (5) , 472-478
- https://doi.org/10.1200/jco.2006.07.2983
Abstract
Purpose: Lung cancer is a leading cause of cancer death worldwide. Although smoking remains the predominant cause of lung cancer, lung cancer in never smokers is an increasingly prominent public health issue. However, data on this topic, particularly lung cancer incidence rates in never smokers, are limited. Methods: We reviewed the existing literature on lung cancer incidence and mortality rates among never smokers and present new data regarding rates in never smokers from the following large, prospective cohorts: Nurses’ Health Study; Health Professionals Follow-Up Study; California Teachers Study; Multiethnic Cohort Study; Swedish Lung Cancer Register in the Uppsala/Örebro region; and First National Health and Nutrition Examination Survey Epidemiologic Follow-Up Study. Results: Truncated age-adjusted incidence rates of lung cancer among never smokers age 40 to 79 years in these six cohorts ranged from 14.4 to 20.8 per 100,000 person-years in women and 4.8 to 13.7 per 100,000 person-years in men, supporting earlier observations that women are more likely than men to have non–smoking-associated lung cancer. The distinct biology of lung cancer in never smokers is apparent in differential responses to epidermal growth factor receptor inhibitors and an increased prevalence of adenocarcinoma histology in never smokers. Conclusion: Lung cancer in never smokers is an important public health issue, and further exploration of its incidence patterns, etiology, and biology is needed.Keywords
This publication has 69 references indexed in Scilit:
- Polymorphisms in thehMSH2Gene and the Risk of Primary Lung CancerCancer Epidemiology, Biomarkers & Prevention, 2006
- Cancer Surveillance Research: a Vital Subdiscipline of Cancer EpidemiologyCancer Causes & Control, 2005
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Metabolic gene polymorphisms and lung cancer risk in non-smokersMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005
- GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: a population-based studyCarcinogenesis: Integrative Cancer Research, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Lung adenocarcinoma and human papillomavirus infectionCancer, 2004
- Occupation and Lung Cancer in Non-SmokersReviews on Environmental Health, 2003